Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Krystexxa Market Growth Potential: How Will Market Size Shift Through 2030?
Historically, the observed growth was propelled by the limitations inherent in conventional gout treatments, the escalating prevalence of chronic gout, the proven clinical efficacy of pegloticase, an increase in co-occurring medical conditions, and the expansion of specialized rheumatology practices.
The anticipated growth over the forecast period is primarily driven by an expanding population of patients with refractory gout, an increase in referrals to specialized clinics, the enlargement of infusion service offerings, supportive reimbursement frameworks for biologic drugs, and a persistent unmet need in severe gout. Concurrently, major developments during this period are expected to include an escalation in biologic therapies for refractory gout, a heightened emphasis on uric acid-lowering enzyme treatments, specialized care management for individuals with chronic gout, the broadening of infusion-based rheumatology care, and an increasing adoption of treatments in severe and therapy-resistant cases.
Get A Free Sample Report With In-Depth Market Insights:
Krystexxa Market Demand Drivers: What’s Powering Industry Growth?
The Krystexxa market is projected to expand significantly due to the rising occurrence of gout disease. Gout is an arthritic condition characterized by the accumulation of uric acid crystals in the joints, leading to inflammation, pain, and swelling. This elevated incidence of gout is attributed to various factors such as unhealthy dietary habits, obesity, aging, certain medications, genetic predispositions, chronic kidney disease, a sedentary lifestyle, and co-existing conditions like high blood pressure and diabetes. Krystexxa (pegloticase) provides relief to gout patients by reducing uric acid levels in the blood, specifically addressing chronic gout that is resistant to conventional treatments. This action helps to decrease the frequency and severity of gout flare-ups and alleviates the painful symptoms associated with the condition. As an illustration, a report in June 2024 by Rheumatology and Therapy, a US-based international peer-reviewed medical journal, projected that the prevalence of comorbid gout and chronic kidney disease in the United States would climb from 7.9 million in 2023 to 8.6 million in 2027, then to 9.2 million in 2031, eventually reaching 9.6 million in 2035. This signifies a 29% increase from 2023 to 2035. Thus, the escalating incidence of gout disease is a key impetus for the Krystexxa market.
Krystexxa Market Segment Performance And Emerging Opportunities
The krystexxa market covered in this report is segmented –
1) By Formulation: Injectable Formulation (Lyophilized Powder), Ready-To-Use Solutions
2) By Indication: Treatment Of Chronic Gout, Management Of Hyperuricemia In Gout Patients, Treatment Of Refractory Gout
3) By Patient Demographics: Adult Patients, Elderly Patients, Patients With Comorbid Conditions
4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies
5) By End User: Hospitals, Specialty Clinics, Rheumatology Practices, Home Healthcare Providers
Krystexxa Market Innovation Trends: What Developments Are Reshaping The Industry?
A significant trend in the Krystexxa market centers on advancing immunomodulatory strategies, such as the rheumatology research dissemination initiative, to enhance the visibility of clinical evidence, aid in making informed therapeutic decisions, and strengthen stakeholder comprehension of emerging progress in managing inflammatory and autoimmune diseases. The rheumatology research dissemination initiative specifically refers to an organized scientific communication endeavor designed to present, share, and promote new clinical findings, therapeutic data, and investigational insights within rheumatology. For instance, in June 2024, Amgen Inc., a US-based biotechnology company, showcased innovative rheumatology research at the European Alliance of Associations for Rheumatology (EULAR) 2024 Congress, highlighting new clinical data pertinent to Krystexxa (pegloticase). This research unveiled expanded evidence concerning treatment response patterns, patient-reported outcomes, and immunologic behavior when employing advanced therapeutic combinations. Krystexxa, a PEGylated uricase enzyme therapy, continues to demonstrate unique clinical benefits for adults with uncontrolled chronic gout by utilizing precision immune modulation to improve efficacy and manage anti-drug antibody formation. These recent insights, shared by Amgen, reaffirm Krystexxa’s standing as a leading biologic option for severe gout patients who have not responded adequately to conventional therapies.
Krystexxa Market Key Players: Which Companies Lead Industry Competition?
Major companies operating in the krystexxa market are Amgen Inc.
View The Full Krystexxa Market Report:
Krystexxa Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the krystexxa market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the krystexxa market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
